Kornimate/medical-research-clean huggingface dataset:
multiple daily injections and continuous glucose monitoring in diabetes

Conditions: Diabetes Mellitus

Summary: evaluate if addition and use of real time continuous glucose monitoring (rt-cgm) improves glycemic outcome of patients using multiple daily injections (mdi) and self monitoring blood glucose (smbg) testing, who are not at target glycemic control.

the study design includes two cohorts that will be treated separately. phase 1 will include two diabetes cohorts (type 1 diabetes mellitus and type 2 diabetes mellitus) who will be randomized independently into two groups, group 1-cgm and group 2-smbg. the group-1 cgm cohort who have type 1 diabetes mellitus will be eligible for phase 2. phase 2 will include a separate independent randomization of either mdi therapy (group 1a- cgm/mdi) or csii therapy (group 1b-cgm/csii). additional assessments will be made to evaluate the incremental benefits of changing the insulin delivery method from mdi to csii in patients already using cgm. cost effectiveness and quality of life will be measured between the two groups in each phase.

Eligibility criteria:
inclusion criteria: * age 25 years or older * diagnosis of type 1 diabetes mellitus or insulin-requiring type 2 diabetes mellitus * followed regularly by a physician or diabetes educator * using multiple daily injections * stable control of diabetes * willing to wear a device such as pump or continuous glucose monitor exclusion criteria: * recent or planned use of non-insulin injectable hypoglycemic agents * pregnancy or planning to become pregnant during the study * medical conditions that make it inappropriate or unsafe to target an a1c of \<7% * renal disease with glomerular filtration rate \<45 * extensive skin changes/disease that precludes wearing the sensor on normal skin * known allergy to medical-grade adhesives * recent hospitalization or emergency room visit in the 6 months prior to screening resulting in primary diagnosis of uncontrolled diabetes

Keywords: diabetes mellitus
operative or conservative treatment of acute acromioclavicular joint dislocation

Conditions: Acromioclavicular Joint Dislocation

Summary: the study aims to answer if surgery with hook plate for acute dislocation of the acromioclavicular joint (ac joint) grade iii and v according to rockwood is superior to conservative treatment.


Eligibility criteria:
inclusion criteria: * ac joint dislocation grade iii according to rockwood with at least half a clavicular bone width above the acromion or grade v according to rockwood * men and women 18-65 years and able to work * understand spoken and/or written swedish or english language * be able to start treatment within 3 weeks from trauma * consent form signed exclusion criteria: * earlier injury to, or surgery of either of the shoulders * simultaneous fracture of the clavicle or acromion * associates neurovascular injury * severe osteoporosis * open dislocation * open growth plate of the acromion * local skin damage

Keywords: acromioclavicular joint dislocation ac joint dislocation acromioclavicular joint separation hook plate rockwood
a study for moderate osteoarthritis of the knee

Conditions: Osteoarthritis

Summary: this is a study to determine whether flexsure is safe, tolerable and effective in relieving symptoms of moderate osteoarthritis of the knee.

primary efficacy variable: number of patients showing 20% reduction from baseline in the womac - pain subscale secondary efficacy variables: * number of patients showing a 50% reduction from baseline in the womac - pain subscale * number of patients showing a 20% reduction from baseline in vas-pain * number of patients showing a 50% reduction from baseline in vas- pain * mean change (percentage reduction) in womac scores for pain, stiffness and physical function from baseline, as compared to placebo * mean change (percentage reduction) in vas - pain, as assessed at clinic visits and by daily records in patient diary (first two weeks only) * consumption of rescue medication * investigator's global assessment of efficacy * subject's global assessment of efficacy

Eligibility criteria:
inclusion criteria: * ambulatory male or female patients aged 30-65 years, and diagnosed of oa of the knee according to the acr clinical and radiographic criteria * ara functional class ii or iii * kellgren lawrence radiological severity of grade ii, grade iii oa knee * maximal oa pain on movement, as measured on a 0-100 visual analog scale (vas) should be more than 40 and less than 80 in the previous 24 hrs at screening and baseline visits exclusion criteria: * conditions that can mimic oa knee pain, e.g. rheumatoid arthritis, systemic lupus erythematosus, gout, psoriatic arthritis, pseudo gout or pain due to malignant disease * bmi \>35 kg/m2 * indication of surgery for oa knee * arthroscopy of either knee in the past year * use of analgesics or any other symptom-relieving medication within 7 days of screening * use of systemic steroids or herbal medication for oa within 4 weeks of screening * use of vit. d3 injections, glucosamine sulphate, chondroitin sulphate, diacerin, alendronate in the past 3 months * administration of intra-articular steroids in the past 3 month or hyaluronic acid in the last 9 months * history of osteoporotic/ osteoarthritic fractures within the past 6 months * pregnant or lactating women or women with inadequate contraceptive measures * evidence or clinical suspicion of any major medical conditions (e.g. uncontrolled diabetes mellitus, uncontrolled hypertension, cardiovascular disease, thyroid, hepatic, renal dysfunction) * presence of any clinically significant laboratory anomaly * known cases of aids (hiv positive) * history of coronary angioplasty/cabg within the past 2 years * moderate to severe peripheral neuropathy or other neurological disorders * alcohol abuse, medication or drug dependence * concurrent or previous participation in a clinical study within previous 6 weeks
effects of pioglitazone in hypertensive patients

Conditions: Hypertension; Insulin Resistance

Summary: insulin resistance is often complicated with hypertension. age and inflammation play important roles in insulin resistance. some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. the aim of this study to evaluate the effect of pioglitazone compared with glimepiride on age, inflammatory cytokines and cardiac markers (bnp and echo) in hypertensive patients during oral glucose tolerance test.


Eligibility criteria:
inclusion criteria: * hypertension with insulin resistance exclusion criteria: * chronic systolic heart failure, acs

Keywords: hypertension insulin resistance oral glucose tolerance test age inflammatory cytokine
study of visceral fat in type2diabetic patients and its relation to microvascular complications

Conditions: Visceral Fat; Insulin Resistance

Summary: study the correlation between mets ir and visceral fat in type 2 diabetes and its relation to microvascular complication

the metabolic score for insulin resistance (mets-ir) is a metabolic index developed with the aim to quantify peripheral insulin sensitivity in humans; it was first described under the name mets-ir by bello-chavolla et al in 2018. it was developed by the metabolic research disease unit at the institute national de ciencias médicas salvador zubirán and validated against the euglycemic hyperinsulinemic clamp and the frequently-sampled intravenous glucose tolerance test in mexican population.it is a non-insulin-based alternative to insulin-based methods to quantify peripheral insulin sensitivity and an alternative to the homeostatic model assessment (homa-ir) and the quantitative insulin sensitivity check index (quicki). very limited research correlate between visceral obesity and microvascular complications in type 2 diabetic patients and how can the metabolic score for insulin resistance predict visceral obesity and microvascular complications in type2 diabetic patients. in this study the investigators will search for these correlations.

Eligibility criteria:
inclusion criteria: * age \> 18 years both male and female subjects subjects capable of giving consent and voluntarily willing to participate in the study exclusion criteria: * chronic kidney disease patients any nondiabetic nephropathy patients patients affected by hypertension patients affected by ocular disorders neuropathies of other etiologies like chronic liver disease patients, alcoholics, or drug addicts critically ill patients of type 2 diabetes mellitus patients who have not given consent
renal manifestations of ibd

Conditions: Kidney Diseases

Summary: to detect whether patients with inflammarory bowel disease (ibd) have some degree of renal involvement and also to determine if associated with disease activity or not.

inflammatory bowel diseases (ibd) comprise two types of chronic intestinal disorders: crohn's disease (cd) and ulcerative colitis (uc). cd involves the ileum and colon, but it can affect any region of the intestine, often discontinuously. uc involves the rectum and may affect part of the colon or the entire colon (pancolitis) in an un interrupted pattern. in crohn's, the inflammation is often transmural, whereas in ulcerative colitis the inflammation is typically confined to the mucosa . the extraintestinal manifestations of ibd are common and may occur in 25%-40% of patients. inflammatory manifestations in the skin, eyes, liver and joints are considered primary manifestations. development of primary extra intestinal manifestation appears to increase the risk of developing a second extra intestinal manifestation. most ibd patients with extra intestinal manifestations have colonic inflammation, although some patients develop them prior to the onset of colonic symptoms. extra intestinal manifestations are usually present at the time of active phase of ibd . in recent years, there have been reports on renal and urologic complications of ibd. they were mostly found to be related to ureteral obstruction by oxalate stones, cystitis, acute tubular necrosis due to volume depletion and aa amyloidosis. nephrolithiasis and obstructive uropathy are especially seen with small bowel dysfunction. in a great proportion of ibd patients, ureteral obstruction is not caused by stones. this non calculus obstruction can occur in 50%-73% of cd patients and 50% of uc patients, and is usually caused by retroperitoneal local inflammation or by surgical complication (sutures) or colon cancer . there have also been reports of interstitial nephritis, mainly due to applied anti-inflammatory therapy, such as 5-aminosalicylic acid (5-asa). serious renal impairment is reported to occur in 1 of 500 patients treated with 5-asa derivative. on the other hand, there are some reports that renal tubular damage is an extra intestinal manifestation of ibd and not a toxic side effect of anti-inflammatory therapy using 5-asa or sulfasalazine. furthermore, renal failure due to glomerulonephritis (gn) caused by the immune complex has been reported in several cases as an extraintestinal manifestation of ibd.

Eligibility criteria:
inclusion criteria: - a ny patients with ibd exclusion criteria: pregnant kidney disease
activity-based training after myocardial infarction

Conditions: Myocardial Ischemia; Activities of Daily Living

Summary: cardiovascular diseases cause high morbidity and mortality, resulting in disability, medical complications and comorbidities. patients who have mi experience motor, cognitive and sensory impairments, reduced quality of life and burdened the national economy. cardiac rehabilitation aims to optimize patients' health services, reduce physical and psychological effects and increase activity return performance. the rehabilitation process includes physical activities and patient education starting in the early stages after mi. psychosocial support and occupational therapy can accelerate patients' recovery and return to daily activities. since there are inadequacies in the literature on this subject, this study aims to provide an effective educational intervention for patients who have mi and to examine a safe return to activity.


Eligibility criteria:
inclusion criteria: * diagnosis of myocardial infarction (st elevation or non-st elevation) * ejection fraction \> 40% exclusion criteria: * ejection fraction \< 40% * presence of exercise-induced ischemia * presence of orthopedic or neurological disorder that will affect the current study * presence of pulmonary disease that will affect the current study (copd, asthma) * presence of visual impairment * presence of malignancy

Keywords: myocardial ischemia activities of daily living metabolic equivalent
clinical and immunological features of the cmv infection atypical course in immunocompetent individuals

Conditions: CMV

Summary: current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients with acute cmv infection. а new method for the early detection of immunological and clinical signs of thromboembolic complications of cmv infection in immunocompetent individuals and the treatment of patients in this category will be developed.

* evaluate the immune status main indicators that characterize the activation of immune system, immunosuppression and anergy (myeloid suppressor cells, t-regulatory cells, t-cells according to the stages of differentiation (naive - effector - memory), activated t-cells); * identify and characterize immunological disorders in patients with cmv infection complicated by thromboembolism of various localization; * determine the presence and quantitative content in plasma / serum and neutrophils of the cmv genetic material by real-time pcr; * study humoral immunity to cmv (igm / igg antibodies to cmv in serum); * determine the content of cmv specific t-cells in peripheral blood; * develop a method for the early detection of immunological and clinical signs of thromboembolic complications of cmv infection in immunocompetent persons and treatment of patients in this category.

Eligibility criteria:
inclusion criteria: * age 18 - 80 years; * fever of not clear etiology * confirmed cmv infection exclusion criteria: * hiv infection * taking hormones, cytostatics; * drug addiction * malignant neoplasms over the past 5 years. * active viral hepatitis or liver cirrhosis; * immunosuppressive conditions of any etiology

Keywords: cytomegalovirus
global epidemiologic study of preexisting immunity to aav in adults with severe hemophilia

Conditions: Hemophilia A; Hemophilia B

Summary: assess the seroprevalence of neutralizing antibodies (nab) to aav in adults with severe hemophilia a (coagulation factor viii \[fviii\] \<1%) or moderately severe to severe hemophilia b (coagulation factor ix \[fix\] ≤2%).


Eligibility criteria:
inclusion criteria: 1. participant is male between 18 and 75 years old at the time of screening. 2. established severe hemophilia a (plasma factor viii (fviii) activity \<1%) or b (plasma factor ix (fix) activity ≤2%). 3. provision of signed informed consent form (icf). 4. participant is willing and able to comply with the requirements of the protocol. exclusion criteria: 1. bleeding disorder(s) other than hemophilia a or b. 2. personal laboratory evidence of having developed inhibitors to fviii or fix protein at any time (≥0.6 bethesda units \[bu\] on any single test). 3. currently receiving systemic immunosuppressive therapy, cytotoxic chemotherapy, immunoglobulin therapy, or monoclonal antibody therapy. 4. received systemic antiviral and/or interferon therapy within 30 days of blood draw, with the exception of treatment for human immunodeficiency virus (hiv). 5. currently receiving ribavirin and/or interferon based therapy for active hepatitis c virus (hcv). 6. received immunoglobulin therapy or plasma infusion within 120 days of the blood draw. 7. has a known immune deficiency other than hiv. 8. has lymphocyte or plasma cell malignancies. 9. participant is a family member or employee of the investigator.
impact on mental, physical, and cognitive functioning of a critical care stay during the covid-19 pandemic

Conditions: Covid19; Critical Care; Postintensive Care Syndrome

Summary: intensive care unit (icu) survivors and their families frequently present mental, cognitive and physical impairments lasting years. the ongoing pandemic could affect the duration, variety, and severity of these impairments. our aim is to determine the impact of the covid-19 pandemic on the physical, mental, and cognitive health of survivors, the experience of their families and their treating healthcare professionals in the long-term. this is a prospective, multicentre, mixed-methods cohort study in seven chilean icus. the perceptions of family members regarding the icu stay and the later recovery will be explored 3 months after discharge. health care professionals will be invited to discuss the challenges faced during the pandemic using semi-structured interviews.


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years old) * mechanically ventilated for at least 48 hours exclusion criteria: * unable to walk independently 2 weeks prior to icu admission (with or without a gait aid) * s5q \< 5 or cam-icu positive within 72 hours after icu discharge * patient who do not understand or speak spanish * patient unable to communicate verbally * burn or severe trauma as admission diagnosis * any neurological disorder (i.e. spinal cord injury, stroke and brain tumours) as admission diagnosis * transferred to a non-participating study centre before icu discharge assessment * recent prolonged hospital stay (extended by more than 3 months)

Keywords: covid19 critical care postintensive care syndrome rehabilitation follow-up
pharmacokinetics of cidofovir during continuous venovenous hemofiltration

Conditions: Cytomegalovirus Retinitis; Acute Renal Failure

Summary: cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against herpesviruses. its potency in inhibiting hcmv has been shown in conventional in vitro studies. it is approved for the systemic treatment of human cytomegalovirus (hcmv) retinitis in patients with aids and as a second line therapy for hcmv infections not responding to ganciclovir or foscarnet. in intensive care patients continuous venovenous haemofiltration (cvvh) is a well-established extracorporal renal replacement therapy with a high clearance rate. pharmacokinetic studies of antifungal agents in critically ill patients treated with cvvh are rare. elimination of any given drug by renal replacement therapy is determined by several major factors which are membrane specific, due to physico-chemical properties of the drug and characteristics of the renal replacement technique used. study objective the trial is conducted to investigate the pharmacokinetics of cidofovir during cvvh in critically ill patients. it is suspected that hemofiltration will influence cidofovir plasma levels.


Eligibility criteria:
inclusion criteria: * age 18 to 75 years * suspected of proven hcmv infection * suspected or proven resistancy of hcmv to the first line therapy (ganciclovir / foscarnet). * continuous venovenous hemodiafiltration (cvvhdf) due to acute or chronic renal failure. exclusion criteria: * known history of hypersensitivity to cidofovir or probenecid. * an expected survival of less than three days. * known alcohol dependency, epilepsy, pregnancy or liver failure. * infection with a ganciclovir or foscarnet susceptible hcmv strain

Keywords: cidofovir cvvh renal replacement therapy hcmv pharmacokinetics of cidofovir during cvvh continuous venovenous hemofiltration
efficacy of different durations of dual and quadruple regimens for helicobacter pylori eradication

Conditions: HELICOBACTER PYLORI INFECTIONS

Summary: the study aimed to compare the efficacy and safety of dual and quadruple regimens with different durations (7-day, 10-day, 14-day) for the eradication of helicobacter pylori. subjects were randomized to receive the intervention and were reviewed by 13c-urea breath test after 6 weeks. the eradication rates, adverse reaction rates and patient adherence were calculated.


Eligibility criteria:
inclusion criteria: 1. patients aged 18-70 years old 2. patients with h.pylori infection (13c/14c-urea breath test) 3. patients without previous treatment for h. pylori eradication exclusion criteria: 1. patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75% 2. patients with active gastrointestinal bleeding 3. patients with a history of upper gastrointestinal surgery 4. patients allergic to treatment drugs 5. patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitor within 2 weeks 6. patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial 7. patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse 8. patients who are unwilling or incapable to provide informed consents
glasses against transmission of sars-cov-2 (covid-19) in the community

Conditions: COVID-19; Respiratory Tract Infections

Summary: in this trial the researchers plan to recruit 25,000 volunteers to be randomly allocated either wearing sunglasses or ordinary glasses in public spaces where they are close to other people, or not wear glasses in such circumstances. for each participant the trial period is 2 weeks, after which they will be asked to complete a brief questionnaire which includes questions about results of covid-19 tests during the trial period.

a systematic review of observational studies indicated that eye protection may be an effective measure to prevent sars-cov-2 infections. randomized trials are needed to assess whether the observed associations are caused by protection of the eye or confounding factors such as other systematic differences between users and non-users of eye protection, co-interventions, or changes in covid-19 incidence when comparisons were done over time. this is a pragmatic, virtual, parallel group, 1:1 randomized, superiority trial. the researchers will recruit and randomize participants via an online portal. the trial will be fully remote and virtual without any personal interaction between investigators and participants. all members of the public are eligible who confirm that they are at least 18 years of age, do not regularly wear glasses, have not contracted covid-19 since december 15th 2021, and are willing to be randomized to wear, or not wear glasses in public when close to other people, for a 2-week period. persons who are dependent on visual aids but typically use contact lenses are eligible. the participants will be randomized (1:1) to wear glasses (sunglasses or other types of glasses) in public spaces when close to others (public transport, shopping centers etc.), or to the control group. the control group will be asked not to wear glasses in public spaces when close to others. the primary outcome is positive test for covid-19. the researchers aim to include about 25,000 participants to have a statistical power of 80% to detect a relative risk reduction of 25% for the primary outcome.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * owns or can borrow glasses that can be used (e.g. sun-glasses) * willing to be randomized to wear, or not wear glasses outside the home when close to others, for a 2-week period. * provides informed consent exclusion criteria: * does regularly wear glasses (contact lenses are accepted) * contracted covid-19 after december 15th 2021.

Keywords: covid-19 prevention protection